

Session Title: #78: Neurologic Complications of Cancer Therapies

Session Type: Education Session

Date: Friday, June 4

Location: S100b

Time: 1:00 PM - 2:15 PM

- Peripheral Neuropathies
David Schiff, MD
 - CNS complications (including effects of targeted therapies)
Patrick Y. Wen, MD
 - Radiation and chemotherapy effects on cognition (including chemo brain)
Michelle Monje, MD, PhD
-

Session Title: #235: Sex and the Survivor

Session Type: Extended Education Session

Date: Friday, June 4

Location: E Arie Crown Theater

Time: 1:00 PM - 3:15 PM

- Overview of Current Strategies to Prevent and Treat Cancer-Related Sexual Dysfunction
Leslie R. Schover, PhD
- Preventing and Treating Sexual Dysfunction in Women with Breast Cancer
Patricia A. Ganz, MD
- Gynecologic Approach to Women's Cancer-Related Sexual Dysfunction
Stacy Tessler Lindau, MD, MAPP
- Urologic Treatment of Men's Cancer-Related Sexual Dysfunction
John Mulhall, MD
- Sexuality in survivors of colorectal cancer
Francesco Di Fabio, MD

- SPIRIT: Peer Counseling to Promote Reproductive Health in African-American Breast Cancer Survivors

Michelle Marion Rhodes, PhD

- Sexual Impact of Being at High Genetic Risk for Cancer

Sharon L. Bober, PhD

Session Title: #237: Cancer and Thrombosis: Risk, Prevention, and Treatment

Session Type: Extended Education Session

Date: Friday, June 4

Location: E354a

Time: 1:00 PM - 3:15 PM

- Review currently available guidelines for the prevention of cancer-associated thrombosis

Gary H. Lyman, MD, MPH

- Review the incidence and prevalence of cancer-associated thrombosis

Alok A. Khorana, MD

- Risk of VTE in patients receiving newer cancer therapies

Howard A. Liebman, MD

- Prevention of VTE in hospitalized medical patients

Charles W. Francis, MD

- Prevention of VTE in surgical cancer patients

Ajay Kumar Kakkar, MD

- Prevention of VTE in ambulatory cancer patients receiving chemotherapy

Mark Norman Levine, MD

- Current and future clinical trials of VTE prophylaxis in cancer patients

Anna Falanga, MD

- Diagnosis and initial treatment of VTE in cancer patients

Craig M. Kessler, MD

- Special populations and extended anticoagulation of cancer patients for the prevention of recurrent VTE prevention of recurrent VTE

Agnes Y. Y. Lee, MD, MSc, FRCP(C)

Session Title: #108: Update on Patient Safety: Basic Science, Practical Strategies in Oncology Practice, and Discussing Complications

Session Type: Education Session

Date: Friday, June 4

Location: E Arie Crown Theater

Time: 3:30 PM - 4:45 PM

- Update on Patient Safety: Basic Science, Practical Strategies in Oncology Practice, and Discussing Complications

James Bagian, MD

- Quality of Care and Patient Safety in Oncology

Saul Weingart, MD, PhD

- Update on Patient Safety: Basic Science, Practical Strategies in Oncology Practice, and Discussing Complications

Glenn D. Steele, MD, PhD

Session Title: #43: Electronic Health Records in Oncology: A requirement for 2014

Session Type: Education Session

Date: Friday, June 4

Location: E353

Time: 4:30 PM - 5:45 PM

- So you want me to adopt EHR by 2014?

Jonathan B. Perlin, MD, PhD, MSHA, FACP, FACMI

- Interoperability: Getting the relevant information to the right place in real time

Peter Paul Yu

- Getting more out of your EHR

Lawrence N. Shulman, MD

Session Title: #19: Cancer Fatigue and Contributing Factors: Recognition and Treatment

Session Type: Education Session

Date: Saturday, June 5

Location: E354b

Time: 8:00 AM - 9:15 AM

- Cancer-Related Fatigue: Who Gets It and How Long Does It Last?

- Non Pharmacologic Interventions to Decrease Fatigue

Bernadine Cimprich, RN, PhD, CS, FAAN

Session Title: #142: When Onco-cardiology Meets Cardio-oncology: A Global Perspective

Session Type: Clinical Problems in Oncology Session

Date: Saturday, June 5

Location: E451a

Time: 8:00 AM - 9:15 AM

- Patterns of cardiac toxicity with novel therapies and management issues

Erica L. Mayer, MD

- Pathophysiology of cardiotoxicity in chemotherapy and targeted therapy

Daniel John Lenihan, MD

- Cardiac problems in oncology patients beyond cardiotoxicity - a road to cancer cachexia

Stefan D Anker, MD, PhD

Session Title: #268: Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Session Type: Special Session

Date: Saturday, June 5

Location: N Hall B1

Time: 9:30 AM - 12:00 PM

- Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Daniel D. Von Hoff, MD

Session Title: #5: A Family's Year with Cancer

Session Type: Education Session

Date: Saturday, June 5

Location: S404

Time: 1:15 PM - 2:30 PM

- The Impact of Cancer on Families

Lidia Schapira, MD

- A Family's Year with Cancer

David Treadway, PhD

- A Family's Year with Cancer

Kate Treadway, MD

Session Title: #68: Management of Side Effects of the Treatment of Colorectal Cancer (including eQuestions)

Session Type: Education Session

Date: Saturday, June 5

Location: E354b

Time: 1:15 PM - 2:30 PM

- Managing and reducing side effects of pelvic radiation

Bruce D. Minsky, MD

- Dermatologic toxicities of targeted therapy in colorectal cancer

Mario E. Lacouture, MD

- Management of oxaliplatin-induced neurotoxicity

Howard S. Hochster, MD

Session Title: #163: Patient and Survivor Care

Session Type: Oral Abstract Session

Date: Saturday, June 5

Location: E354b

Time: 3:00 PM - 6:00 PM

- Patient and Survivor Care

Barbara A. Murphy, MD

- Patient and Survivor Care

- #9009-Prevalence of hepatitis B surface antigen and hepatitis B core antibody in a population initiating immunosuppressive therapy.

Emmy Ludwig

- Discussion

Sandra L. Wong, MD, MS

- #9010-Yield from risk-based screening in adults treated for cancer in childhood.

Melissa M. Hudson, MD

- #9011-Executive functions in aging adult survivors of childhood leukemia.

Kevin R. Krull

- #9012-Contrasting effects of religious/spiritual support from religious communities versus medical teams on advanced cancer patient end-of-life care.

Tracy A. Balboni

- Discussion

Betty R. Ferrell, RN, PhD, FAAN

- #9013-Effect of YOCAS yoga on sleep, fatigue, and quality of life: A URCC CCOP randomized, controlled clinical trial among 410 cancer survivors.

Karen Michelle Mustian

- #9014-Prevention of pegfilgrastim-induced bone pain (PIP): A URCC CCOP randomized, double-blind, placebo-controlled trial of 510 cancer patients.

Jeffrey J. Kirshner

- #9015-A meta-analysis of results from two randomized, double-blind studies of denosumab versus zoledronic acid (ZA) for treatment of bone metastases.

Allan Lipton, MD

- #9016^ -Efficacy and safety of fentanyl pectin nasal spray versus immediate-release morphine sulphate tablets in the treatment of breakthrough cancer pain.

Marie T Fallon

- Discussion

Teresa Gilewski, MD

Session Title: #167: Highlights of the Day I including Clinical Trials Participation Awards

Session Type: Highlights of the Day

Date: Sunday, June 6

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day I including Clinical Trials Participation Awards

Everett E. Vokes, MD

- Clinical Trials Participation Awards

Douglas W. Blayney, MD

- Discussion: Lymphoma and Plasma Cell Disorders

Bruce D. Cheson, MD

- Discussion: Lung Cancer - Local/Regional and Adjuvant Therapy

Alan B Sandler, MD

- Discussion: Patient and Survivor Care

Gretchen Genevieve Kimmick, MD

- Discussion: Melanoma/Skin Cancers

F. Stephen Hodi, MD

Session Title: #21: Caregiving to Elderly Patients: Clinical, Ethical, and Psychosocial Challenges

Session Type: Education Session

Date: Sunday, June 6

Location: S100a

Time: 8:00 AM - 9:15 AM

- Ethical and social implications of caregiving to elderly cancer patients

Antonella Surbone, MD, PhD, FACP

- Beyond the possible: appraising the needs of elderly cancer patients' caregivers

Lea Baidar, PhD

- The spirituality of the home caregiver

Lodovico Balducci, MD

Session Title: #130: Immunosuppression in Patients with Lymphoma and Myeloma

Session Type: Clinical Problems in Oncology Session

Date: Sunday, June 6

Location: E451a

Time: 8:00 AM - 9:15 AM

- Prolonged B-cell Suppression from anti-CD20 therapies: What are the risks?

Myron Stefan Czuczman, MD

- Impact of T-cell Directed Therapies on Immunocompetence

Francine M. Foss, MD

- Prevention, Surveillance and Management of Viral Reactivation in the setting of Immunosuppressive Therapies for Lymphoma and Myeloma

John A. Zaia, MD

Session Title: #229: Pharmacologic Treatment of Cancer Related Fatigue: Does it Make a Difference?

Session Type: Clinical Science Symposium

Date: Sunday, June 6

Location: E354a

Time: 9:45 AM - 11:15 AM

- Pharmacologic Treatment of Cancer Related Fatigue: Does it Make a Difference?

Barbara A. Murphy, MD

- Pharmacologic Treatment of Cancer Related Fatigue: Does it Make a Difference?

Thomas J. Smith, MD

- #9004-Long-acting methylphenidate for cancer-related fatigue: NCCTG trial N05C7.

Debra L. Barton

- #9005-Factors associated with response to methylphenidate in advanced cancer patients with cancer-related fatigue.

Sriram Yennurajalingam

- #9006-A randomized double-blind placebo-controlled study of oral coenzyme Q10 to relieve self-reported cancer-treatment-related fatigue in newly diagnosed breast cancer patients.

Glenn Jay Lesser

- Discussion

Thomas J. Smith, MD

Session Title: #96: Survivorship in Lymphoma

Session Type: Education Session

Date: Sunday, June 6

Location: E354a

Time: 11:30 AM - 12:45 PM

- Imaging in Lymphoma Patients: Who, when, how and how long?

Rebecca L. Elstrom, MD

- Long Term Toxicities of Lymphoma Therapy

David J. Straus, MD

- Psychosocial Issues of Lymphoma Survivors: Cured but not healed?

Jennifer Mills, MSW, MPH

Session Title: #132: Lifestyle and Pharmacologic Therapeutics in Colorectal Cancer Survivors: What to Do after Adjuvant Therapy?

Session Type: Clinical Problems in Oncology Session

Date: Sunday, June 6

Location: E451a

Time: 11:30 AM - 12:45 PM

- Pharmacologic interventions to lower the risk of tumor recurrence in patients with resected colorectal cancer

David P. Ryan, MD

- Beyond standard surgery and chemotherapy to lower the risk of tumor recurrence in patients with resected colorectal cancer

Jeffrey A. Meyerhardt, MD, MPH

Session Title: #220: Optimizing Care of the Elderly and Underserved

Session Type: Clinical Science Symposium

Date: Sunday, June 6

Location: S100a

Time: 11:30 AM - 1:00 PM

- Optimizing Care of the Elderly and Underserved
Gretchen Genevieve Kimmick, MD
 - Optimizing Care of the Elderly and Underserved
Jennifer A. Ligibel, MD
 - #9000-The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score: Design and validation.
Martine Extermann, MD
 - #9001-Predicting chemotherapy toxicity in older adults with cancer: A prospective 500-patient multicenter study.
Arti Hurria, MD
 - Discussion
Hyman Bernard Muss, MD
 - #9002-Racial differences in receipt of guideline-recommended treatment in men with low-, intermediate-, and high-risk prostate cancer (CaP): A population-based study.
Ronald C. Chen
 - #9003-Factors contributing to high symptom burden during chemotherapy for advanced lung cancer: The risk of being underserved.

Charles S. Cleeland
 - Discussion
Cathy Bradley, PhD
-

Session Title: #143: Plenary Session including Science of Oncology Award and Lecture

Session Type: Plenary Session

Date: Sunday, June 6

Location: N Hall B1

Time: 1:00 PM - 4:00 PM

- Plenary Session including Science of Oncology Award and Lecture
Douglas W. Blayney, MD
- Plenary Session including Science of Oncology Award and Lecture
Daniel F. Hayes, MD
- Plenary Session including Science of Oncology Award and Lecture
Frank McCormick, PhD, FRS

- #LBA1-Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): A Gynecologic Oncology Group study.

Robert A Burger

- Discussion

Elizabeth A. Eisenhauer, MD

- #2-Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC).

Elisabeth A. Quoix

- #3-Clinical activity of the oral ALK inhibitor, PF-02341066, in ALK-positive patients with non-small cell lung cancer (NSCLC).

Yung-Jue Bang

- Discussion

Martin J. Edelman, MD

- #4-A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.

Steven O'Day, MD

- Discussion: Ipilimumab: The light at the end of the tunnel?

Vernon K Sondak, MD

Session Title: #88: Physical Activity in Cancer Populations: What's New?

Session Type: Education Session

Date: Sunday, June 6

Location: E354b

Time: 4:45 PM - 6:00 PM

- Physical Activity and Cancer: Overview and Implications for Survivorship

Jennifer A. Ligibel, MD

- Randomized trials of exercise in cancer patients: Health-related fitness and patient-reported outcomes

Kerry S. Courneya, PhD

- Exercise Testing and Prescription for Cancer Survivors: Guidelines from the American College of Sports Medicine

Kathryn Schmitz, PhD, MPH

Session Title: #131: Incidental Findings on Imaging in the Patient with Cancer: A Prudent Approach to Evaluation and Management

Session Type: Clinical Problems in Oncology Session

Date: Sunday, June 6

Location: E451a

Time: 4:45 PM - 6:00 PM

- The Incidental Renal Mass: Evaluation and Management in the Cancer Patient

Scott Michael Gilbert, MD, MS

- The Incidental Adrenal Mass: Evaluation and Management in the Cancer Patient

J. Stuart Wolf, Jr., MD

- The Incidental Pulmonary Nodule: Evaluation and Management in the Cancer Patient

David E. Ost, MD

Session Title: #168: Highlights of the Day II including Partners in Progress Award

Session Type: Highlights of the Day

Date: Monday, June 7

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day II including Partners in Progress Award

Douglas W. Blayney, MD

- Highlights of the Day II including Partners in Progress Award

Kim Allyson Margolin, MD

- Partners in Progress Award Recipient

Ellen V. Sigal, PhD

- Discussion: Genitourinary (Prostate) Cancer

Nicholas J. Vogelzang, MD

- Discussion: Gastrointestinal (Colorectal) Cancer

Howard S. Hochster, MD

- Discussion: Gynecologic Cancer

Claire F. Verschraegen, MD

- Discussion: Myeloma

Jean L. Harousseau, MD

Session Title: #58: Impact of Health Literacy on Health Care, Decision Making and Consent

Session Type: Education Session

Date: Monday, June 7

Location: E353

Time: 8:00 AM - 9:15 AM

- Impact of limited health literacy; assessing literacy and overcoming barriers to limited literacy in delivering health care

Terry C Davis, PhD

- overcoming literacy issues in obtaining informed consent

Cathy A. Coyne, PhD

- Decision making in breast and prostate cancer

Angela Fagerlin, PhD

Session Title: #105: Toward Optimizing Outcomes in Early-stage Testicular Cancer: How Little or How Much Therapy?

Session Type: Education Session

Date: Monday, June 7

Location: E354b

Time: 8:00 AM - 9:15 AM

- Management options for early stage seminoma and non-seminoma

Christian K. Kollmannsberger, MD

- Is RPLND still relevant?

David Peter Wood, MD

- Toxicity and survivorship in testicular cancer survivors. Should it modify what I do?

George J. Bosl, MD

Session Title: #139: The Spectrum of Therapeutic Dilemmas in Kidney Cancer: From Early- to Late-stage Disease

Session Type: Clinical Problems in Oncology Session

Date: Monday, June 7

Location: E451a

Time: 8:00 AM - 9:15 AM

- Diagnosis and Management of the Renal Mass

- Optimal Management of Toxicities Related to Targeted Agents

Tim Eisen, PhD, FRCP

Session Title: #62: Individualizing Therapy for Locally Advanced and Metastatic Urothelial Cancer

Session Type: Education Session

Date: Monday, June 7

Location: S406 (Vista Room)

Time: 9:30 AM - 10:45 AM

- Review of standard and emerging therapies for localized and advanced urothelial cancer

David I. Quinn, PhD, FRACP, MBBS

- Personalizing therapy for urothelial cancer: clinical and molecular biomarkers

Jonathan E. Rosenberg, MD

- How to overcome barriers to the adoption of neoadjuvant therapy for locally advanced urothelial cancer

Ralph deVere White, PhD

Session Title: #50: Family Members and Caretakers: Helping the Family and Helping the Family Help the Patient

Session Type: Education Session

Date: Monday, June 7

Location: E353

Time: 9:45 AM - 11:00 AM

- Family and caregiver needs over the course of the cancer

Barbara Given, PhD, RN, FAAN

- Partner-based interventions to enhance coping and pain management, and reduce distress in individuals with cancer

Francis J. Keefe, PhD

- Capitalizing on the Mother-Daughter bond to promote primary and tertiary prevention. Diet and Exercise Interventions to Promote Weight Loss and Improve Diet and Exercise Behaviors among Overweight Women with Breast Cancer and their Daughters

Wendy Demark-Wahnefried, MD

Session Title: #47: Evolving Standards of Care in Metastatic Castration-resistant Prostate Cancer

Session Type: Education Session

Date: Monday, June 7

Location: E Arie Crown Theater

Time: 11:30 AM - 12:45 PM

- Phase III trial results and the impact on standard of care and trial design

Michael J. Morris, MD

- Second line treatment after docetaxel

Kim N. Chi, MD, FRCPC

- Bone directed therapy for prostate cancer: present standards and potential new options

Evan Y. Yu, MD

Session Title: #210: Patient and Survivor Care

Session Type: General Poster Session

Date: Monday, June 7

Location: S Hall A2

Time: 1:00 PM - 5:00 PM

39A #9042-Denosumab in the treatment of bone metastases from advanced cancer or multiple myeloma (MM): Analyses from a phase III randomized trial.

Saroj Vadhan-Raj

39B #9043-Effects of denosumab versus zoledronic acid (ZA) on pain in patients (pts) with advanced cancer (excluding breast and prostate) or multiple myeloma (MM): Results from a randomized phase III clinical trial.

Roger von Moos

39F #9044-Contraception after breast cancer: Results of a survey among French gynecologists.

Hamid Hocini

39G #9045-Treatment with antidepressant and anti-anxiety medications after breast cancer diagnosis in a large HMO.

Virginia P. Quinn

39H #9046-Development of a functional assessment of chronic illness therapy questionnaire to assess dermatology-related quality of life in patients treated with EGFR inhibitors: FACT-EGFR

40B #9048-Satisfaction with physician-patient discussions on fertility and sexual health among young women with cancer.

Maura M Scanlon

40F #9049-Utility of pre-chemotherapy echocardiographical assessment of cardiac abnormalities.

Narayan Vaderahobali Karanth

40G #9050-Evaluation of pandemic H1N1(2009) influenza vaccine in adults with solid tumor malignancies on active systemic treatment.

Jacob David McGee

40H #9051-Patient-reported side effects from molecularly targeted therapies in renal cell carcinoma (RCC).

Virginia Jean Seery

41A #9052-Impact of the change in service name from "palliative" to "supportive" care on patient referral at a comprehensive cancer center.

Shalini Dalal, MD

41B #9053-Pathophysiological role of hormones and cytokines in cancer cachexia.

Hee-Sook Park

41C #9054-The cancer survivor survey: Using Web-based technology to assess cancer survivor challenges.

Ellen M. Lavoie Smith

41D #9055-Vanderbilt Head and Neck Symptom Survey Version 2.0 (VHNSS 2.0): A tool for the study of long-term oral health consequences of therapy for head and neck cancer (HNC).

Emily Cooperstein

41E #9056-Visual analog scale (VAS) and time trade-off (TTO) preferences for side effects (SE) of chemoradiation (chemoXRT): A comparison of patients (pts) and caregivers (CG).

Diane C. Bodurka

41F #9057-Assessing the magnitude of antiemetic benefit with the addition of the NK1 receptor antagonist (NK1) aprepitant for all platinum agents: Analysis of 1,872 patients (pts) in prospective randomized clinical phase III trials (RCTs).

Richard J. Gralla

41G #9058-The impact of bone health on endocrine treatment strategy in older adults with early-stage, hormone receptor-positive breast cancer.

Sumanta Kumar Pal

41H #9059-Expectations of benefit and symptom burdens among advanced cancer patients (ACP) and spousal caregivers during the course of phase I trials.

Fay J. Hlubocky

42A #9060-Refinement of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) via cognitive interviewing.

Jennifer Hay

42B #9061-Predicting cisplatin-induced ototoxicity in testicular germ cell cancer.

Jose Gerard Monzon

42C #9062-Timing of palliative care referral and symptom burden in phase I cancer patients: A retrospective cohort study.

Henrique Afonseca Parsons

42D #9063-Evaluation of axillary node dissection on measures of upper-extremity disability and overall quality of life after breast cancer surgery .

Sarah A. McLaughlin

42E #9064-Mini-Cog: A brief screening tool for cognitive impairment in older cancer patients.

Mya S Thein

42F #9065-Changes in symptoms and inpatient mortality among advanced cancer patients admitted to a palliative care unit in a comprehensive cancer center.

Masanori Mori, MD

42G #9066-Retrospective mortality comparisons of cancer patients with sepsis syndromes.

David Joyce

42H #9067-Cancer care on a continuum: Maintaining fertility after diagnosis and treatment.

Jaime Melissa Knopman

43A #9068-Use of thermal sensation as a biomarker of response to palliative radiotherapy for cancer-induced bone pain.

Angela C Scott

43B #9069-An evaluation of health literacy (HL) in a consecutive sample of patients (pts) with cancer (ca) of the head and neck (H+N) region.

Kelvin Koay

43C #9070-Innovative quality initiative measurement using Web-based drug dispensing technology with interactive physician queries to evaluate bisphosphonate use across community oncology practices nationwide.

Cynthia G. Baker

43D #9071-The associations between spirituality (S), religiosity (R), and spiritual pain (SP) in advanced cancer patients (AdCa).

Marvin Omar Delgado-Guay, MD

43E #9072-The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash with cetuximab in cancer patients: A meta-analysis.

Yevgeniy Balagula, MD

43F #9073-Use of unnecessary medications by terminally ill cancer patients.

Rachel Riechelmann

43G #9074-Polypharmacy in elderly cancer patients.

Trine Lembrecht Jorgensen, MD

43H #9075-The association between clinical, sociodemographic, and logistic-administrative factors and adherence to completing health-related quality-of-life questionnaires.

Jurgen Vercauteren

44A #9076-Evaluation of variants of the rs1934951 locus of *CYP2C8* and bisphosphonate-related osteonecrosis of the jaw in castrate-resistant prostate cancer (CRPC) patients.

Paul Gustav Kluetz, MD

44B #9077-An exploratory analysis of transfusion risk when initiating darbepoetin alfa (DA) therapy at baseline hemoglobin (Hb) < 9 g/dl vs 9 to < 10 g/dl versus \geq 10 g/dl in patients (pts) with chemotherapy-induced anemia (CIA).

Jean-Luc Re Canon

44C #9078-Interpretation of do-not-resuscitate (DNR) orders among oncology health care professionals and the potential for these orders to influence care for medical issues unrelated to resuscitation.

Chad R. Lund

44D #9079-How accurate is clinician reporting of chemotherapy side effects? A prospective study comparing clinician with patient-reported symptoms.

Sharmistha Ghosh

44E #9080-The effect of palliative care consultations on the end-of-life care in the Veteran's cancer population.

Wilson Gonsalves, Bsc, MD

44F #9081-Validation of first speech-specific questionnaire for English-speaking head and neck cancer (HNC) patients.

Rehan Kazi

44G #9082-Differences in lung cancer clinical trial accrual between a public and university medical oncology clinic.

Stephen j Vara

44H #9083-Barriers to symptom management in oncology.

Betty R. Ferrell, RN, PhD, FAAN

45A #9084-Uridine triacetate: An orally administered, life-saving antidote for 5-FU overdose.

Michael K Bamat, PhD

45B #9085-Differences between old (70-80 years) and very old (80+ years) cancer patients: Results from the IN-GHO registry.

Friedemann Honecker

45C #9086-Depression and EGFR mutation status in stage IV non-small cell lung cancer.

William F. Pirl

45D #9087-Polypharmacy and functional status in older patients with breast, colon, and lung cancers.

Gopi K. Prithviraj

45E #9088-Reactivation of chronic hepatitis B virus in cancer patients receiving immunosuppression: The case for screening.

Robin B Mendelsohn

45F #9089-Osteopenia in survivors of childhood cancer.

Rajaram Nagarajan

45G #9090-Breast cancer survivors perception of family physician (FP) or specialist as principal provider of routine follow-up care.

Eva Grunfeld, MD, D.Phil.

45H #9091-The use of complementary and alternative medicine in patients seen in phase I clinical trials program.

Saneese Stephen

46A #9092-Late toxicity and quality of life in oral cavity and oropharyngeal cancer survivors treated with chemoradiotherapy.

Mafalda Oliveira, MD

46B #9093-What do patients rank as more important in quality-of-life (QL) and patient-reported outcome (PRO) evaluation: Symptoms (Sx) or summative assessments? Results of a 3,860 patient survey in lung, breast, and prostate cancers with implications for drug development.

Harry Raftopoulos

46C #9094[^]-Long-term safety, tolerability, and acceptability of fentanyl pectin nasal spray in the treatment of breakthrough cancer pain.

Allen W. Burton

46D #9095-Randomized trial of combined treatment versus usual care plus antidepressant in depressed oncologic patients: One-year follow-up.

Angela Palao Tarrero

46E #9096-The prognostic role of quality-of-life assessment in lung cancer.

Donald Peter Braun

46F #9097-Predictors of high symptom severity in caregivers of underserved minority cancer patients.

Guadalupe R. Palos, DrPH

46G #9098-Correlates and mediators of worry about breast cancer recurrence.

Nancy K Janz

46H #9099-Role of yoga in modulating fatigue, sleep disturbances, salivary cortisol, and immune measures in breast cancer survivors: A randomized controlled trial.

Rao M Raghavendra

47A #9100-A randomized trial of weekly high-dose calcitriol and weight-bearing exercise for cancer-treatment-induced bone loss (CTIBL) and bone metabolism in ER+ breast cancer (BC) patients.

Luke Joseph Peppone

47B #9101-Longitudinal prospective assessment of sleep disturbance in breast cancer.

Stacy D Sanford

47C #9102-Clinician perceptions of care difficulty and quality of life for lung cancer patients: Results from the ECOG SOAPP study (E2Z02).

Heidi A Hamann

47D #9103-The effect of zoledronic acid on the prevention of bone loss in lymphoma patients receiving first-line therapy.

Jason R. Westin, MD

47E #9104-Pilot evaluation of a stellate ganglion block for the treatment of hot flashes.

Deirdre R Pachman

47F #9105-Geriatric assessment in 347 elderly cancer patients: Study of geriatric factors modifying the cancer treatment plan.

Philippe Caillet

47G #9106-How long have I got? Estimating survival for women starting first-line chemotherapy for metastatic breast cancer (MBC): A systematic review of recent randomized trials.

Belinda Emma Kiely

47H #9107-Assessing the clinical significance of real-time quality of life (QOL) data in cancer patients treated with radiation therapy.

Michele Y. Halyard

48A #9108-Pilot trial of decision aids for patients with advanced breast, lung, colorectal, or prostate cancer.

Lindsay A Dow

48B #9109-National survey of U.S. oncologists' knowledge, attitudes, and practice patterns regarding herb and supplement use by cancer patients.

Richard T. Lee

48C #9110-Patient surveillance following curative-intent treatment for breast carcinoma: Current practice patterns.

Julie A. Margenthaler

48D #9111-Perspectives on the financial burden of cancer care: Concurrent surveys of patients (Pts), caregivers (CGs), and oncology social workers (OSWs).

Martin Eichholz, PhD

48E #9112-Cancer treatment impact on cognitive functioning and quality of life in lung cancer survivors.

Sadhna Kohli

48F #9113-A phase II clinical study of interleukin-11 mutein to treat patients with chemotherapy-induced thrombocytopenia.

Seong-Hyun Ho, DVM

48G #9114-Can the short screening test vulnerable elders survey 13 (VES-13) substitute for the time-consuming comprehensive geriatric assessment (CGA) to identify vulnerable/frail elderly breast cancer patients?

Silvio Monfardini

48H #9115-A real-world evaluation of the effectiveness of dalteparin in the prevention of recurrent venous thromboembolism compared to warfarin in patients with cancer.

W. Robert Simons

49A #9116-A report on the development and validation of first-ever perceptual speech evaluation tool for head and neck cancer (HNC) patients.

Raghav Dwivedi

49B #9117-Adolescent and young adult use of Internet-based cancer survivorship care plans.

Christine E. Hill-Kayser

49C #9118-Predictors of employment (empl) outcomes in outpatients (pts) with common solid tumors: A secondary analysis from E2Z02 (ECOG's SOAPP study).

Amye Tevaarwerk

49D #9119-Enrollment of and toxicity in patients 70 years and older on CTEP/NCI-sponsored, single-agent phase I studies from 1980 to 2005.

Selina L. Chow

49E #9120-A prospective evaluation of symptom change over 4 weeks for outpatients with common solid tumors: Results from E2Z02 (the SOAPP study).

Michael Fisch, MD, MPH

49F #9121-Prechemotherapy hepatitis B virus (HBV) screening in medical oncology patients: A national survey.

Fiona Lee Day

49G #9122-Pregnancy and survival after primary breast carcinoma in young women: A meta-analysis of healthy mother effect studies.

Davide Mauri

49H #9123-Patients' self-assessment of tolerance and quality of life during docetaxel-based chemotherapy: Results from a phase III trial in hormone-naive metastatic prostate cancer patients (GETUG-AFU 15/0403).

Florence Joly

50A #9124-Out-of-pocket (OOP) spending burden for Medicare beneficiaries with cancer.

Xuehua Ke

50B #9125-Development of the lymphedema symptoms intensity and distress survey arm.

Sheila h Ridner

50D #9127-Chemotherapy-induced nausea and vomiting-associated hospital and ER visits in real-world practice: Palonosetron versus other 5-HT3-RA anti-emetic regimens.

Hind T Hatoum

50E #9128-The development and implementation of an institution-based communication skills training program for oncologists.

Philip A. Bialer

50F #9129-Treatment of chemotherapy-induced peripheral neuropathy (CIPN) with topical menthol: A phase I study.

Dawn J Storey

50G #9130-Activation of the MAP-kinase pathway in the skin of patients treated with sorafenib: Clinical and molecular characterization of skin tumors associated with the multikinase inhibitor sorafenib.

Christine Mateus

50H #9131-Quality of life (QOL) and cognitive performance among irradiated brain cancer patients.

Michelle Joy Naughton

51A #9132-The impact of pharmacotherapy on depression and quality of life in patients undergoing a bone marrow transplant (BMT).

Patricia B. Mumby

51B #9133-Delaying skeletal-related events in a randomized phase III study of denosumab versus zoledronic acid in patients with advanced cancer.

David H. Henry

51C #9134-Prevalence of memory problems that limit daily functioning in adult cancer patients: A national representative sample of the U.S. population.

Pascal Jean-Pierre

51D #9135-Natural history of paclitaxel-associated acute pain syndrome (P-APS): NCCTG trial N08C1.

Brandi Reeves

51E #9136-Effect of bevacizumab on the risk of chemotherapy-associated anemia in cancer patients: A meta-analysis.

Amna F Sher

51F #9137-Prevalence of lymphedema and upper-limb impairments after axillary lymph node dissection or sentinel lymph node dissection in breast cancer: A two-year follow-up study.

Aase Sagen

51G #9138-Effect of timing of information on exercise on exercise behavior during cancer treatment: A URCC CCOP protocol.

Lisa Sprod

51H #9139-Gabapentin for the management of hot flashes in prostate cancer survivors: A longitudinal continuation study—NCCTG trial N00CB.

Amanda R Moraska

52A #9140-Testosterone levels and quality of life (QoL) in male patients with hormone-independent cancers (HIC).

Stewart Barry Fleishman

52B #9141-Overall survival in randomized controlled trials of chemotherapy (CT) with or without GCSF support: A systematic review.

Gary H. Lyman, MD, MPH

52C #9142-Disparities in receipt of supportive/palliative care services among women with breast cancer.

Michael T. Halpern

52D #9143-Post-traumatic stress in patients with acute leukemia.

Camilla Zimmermann

52E #9144-Potential plasma biomarkers predicting radiation dermatitis in breast cancer patients.

Julie L. Ryan

52F #9145-The impact of symptom clusters on survival in patients with advanced cancer.

Aynur Aktas, MD

52G #9146-Use of health-related quality of life and clinical data as prognostic tools for survival prediction in a subgroup of metastatic cancer patients.

Chantal Quinten

52H #9147-Effect of GTx-024, a selective androgen receptor modulator (SARM), on stair climb performance and quality of life (QOL) in patients with cancer cachexia.

Mitchell S. Steiner

53A #9148-Effect of gabapentin on anxiety among 306 breast cancer patients: A URCC CCOP study.

Oxana Palesh

53B #9149-Pharmacoeconomics of clinically relevant hypothyroidism and hypertension from sunitinib and sorafenib.

Christine Marie Walko

54A #9150-Randomized phase II trial of carboplatin (C) and gemcitabine (G) with or without dexamethasone (Dex) in patients (pts) with stage IV non-small cell lung cancer (NSCLC).

John Joseph Rinehart

54B #9151-Effect of oral magnesium on hot flashes in breast cancer survivors.

Haeseong Park

55A #9152-PROCHE: A program to monitor side effects among patients treated in a medical oncology outpatient unit.

Florian Scotte

55B #9153-Cardioprotective effect of telmisartan in cancer patients treated with telmisartan.

Mariele Dessi'

55C #9154-Venothromboembolism (VTE) in patients (pts) with acute myelogenous leukemia (AML).

Nhiem V. Luong, MD, MPH

55D #9155-Pharmacokinetic study of pegylated liposomal doxorubicin (PLD) in patients over 70: Association with increasing age and cutaneous toxicity.

Antonio Bononi

55E #9156-Functional disability and aromatase inhibitor-associated arthralgia in breast cancer survivors.

Claire F Friedman

55F #9157-Bone mineral density in childhood cancer survivors (CCS).

Andrew Charles Dietz

55G #9158-Venous thrombosis associated with central venous catheter in cancer patients with surgical chest port (S) or venography-guided arm port insertion (R): A randomized controlled study.

pierre-Yves Marcy

55H #9159-Coping strategies in young women with breast cancer.

Kathryn Jean Ruddy

56A #9160-A practical program for measuring the quality of ambulatory oncology care in the United States: The Quality Oncology Practice Initiative.

Michael N. Neuss

56B #9161-Chemotherapy-associated cardiotoxicity: Timeline of left ventricular function recovery on standard heart failure regimen.

Johannes K Steiner

56C #9162-Biochemical correlates of fatigue in patients at a comprehensive cancer center.

Anjali A. Bharne

56D #9163-Supplemental oxygen for relief of dyspnea in hospice patients.

Laura Ann Joque

56E #9164-Focus on the assessment of physical activity level of patients with cancer cachexia enrolled in a randomized phase III clinical trial.

Giovanni Mantovani

56F #9165-An analysis of prognostic factors of comprehensive geriatric assessment (CGA) and development of a clinical scoring system in elderly Asian cancer patients.

Ravindran Kaneshvaran

56G #9166-Use of a pharmacist/nurse model for the delivery of supportive care in adult oncology clinics at the University of North Carolina Hospital.

Stephen A. Bernard

Session Title: #28: Complications of Myeloma and Myeloma Therapies

Session Type: Education Session

Date: Monday, June 7

Location: E354a

Time: 1:15 PM - 2:30 PM

- Prophylaxis of Venous Thromboembolic Disease associated with Immunomodulatory Agents

Todd M. Zimmerman, MD

- Prevention and Management of Treatment Induced Peripheral Neuropathy

Paul Gerard Guy Richardson, MD

- Myeloma Bone Disease: What's new?

G. David Roodman, MD, PhD

Session Title: #49: Exploiting the Endocrine Axis in Prostate Cancer Therapy: Current Status and Future Directions

Session Type: Education Session

Date: Monday, June 7

Location: E Hall D2

Time: 1:15 PM - 2:30 PM

- Exploiting the endocrine axis in prostate cancer: what are the new targets?

William K. Oh, MD

- Recent advances in endocrine therapy for prostate cancer: new agents, new options

Mary-Ellen Taplin, MD

- Where is endocrine therapy going in the next five years?

Peter Nelson, MD

Session Title: #85: Oral Chemotherapy: A Hard Pill to Swallow

Session Type: Education Session

Date: Monday, June 7

Location: S406 (Vista Room)

Time: 4:45 PM - 6:00 PM

- General issues relevant to oral chemotherapy and patient health care literacy

Merrill J. Egorin, MD

- Drug-drug and food-drug interactions relevant to oral chemotherapy agents

Jan Hendrik Beumer, PhD, PharmD

- Adherence and persistence (or lack thereof) with oral agents. The scope of the problem. What the data say.

Ann H. Partridge, MD

Session Title: #169: Highlights of the Day III

Session Type: Highlights of the Day

Date: Tuesday, June 8

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day III

Kathy Miller, MD

- Discussion: Breast Cancer - Local/Regional and Adjuvant Therapy

Kathy Miller, MD

- Discussion: Lung Cancer - Metastatic

Charles M. Rudin, MD, PhD

- Discussion: Sarcoma

Gary K. Schwartz, MD

- Discussion: Gastrointestinal (Noncolorectal) Cancer

C. D. Blanke, MD

- Discussion: Head and Neck Cancer

Everett E. Vokes, MD

Session Title: #18: Building Bridges for Successful Breast Cancer Survivorship Care

Session Type: Education Session

Date: Tuesday, June 8

Location: E354a

Time: 8:00 AM - 9:15 AM

- Coordination of Care in Breast Cancer Survivors: An Overview
Claire Frances Snyder, PhD
- Impact of Comorbid Conditions on Breast Cancer Survivorship
Sharon Hermes Giordano, MD
- Information and Training Needs of Primary Care Providers to Promote Quality Care for Breast Cancer Survivors
Larissa Nekhlyudov, MD, MPH
- Communication Strategies, Models, and Tools for Partnerships between Primary Care and Oncology Care to Provide Quality Breast Cancer Survivorship Care
Eva Grunfeld, MD, D.Phil.

Session Title: #27: Comparative Effectiveness Research in Oncology: Opportunities and Challenges

Session Type: Education Session

Date: Tuesday, June 8

Location: S404

Time: 8:00 AM - 9:15 AM

- Comparative effectiveness research: what is it and why is it important?
Gary H. Lyman, MD, MPH
- Comparative effectiveness research to address uncertainties in oncology practice
Neal J. Meropol, MD
- Methods of comparative effectiveness research in oncology
Jerome Seidenfeld, PhD

Session Title: #189: Patient and Survivor Care

Session Type: Poster Discussion Session

Date: Tuesday, June 8

Location: E450a

- Patient and Survivor Care

Amy Pickar Abernethy, MD

- Patient and Survivor Care

Janet Lee Abraham, MD

1 #9017-Evaluation of a urea/lactic acid-based topical keratolytic agent (ULABTKA) for prevention of capecitabine-induced hand and foot syndrome (HFS): NCCTG trial N05C5.

Sherry L Wolf

2 #9018-Using the Skindex-16 and CTCAE to assess rash symptoms: Results of a pooled-analysis (N0993).

Pamela J Atherton

3 #9019-CYTAR: A randomized clinical trial evaluating the preventive effect of doxycycline on erlotinib-induced folliculitis in non-small cell lung cancer patients.

Gael Deplanque

4 #9020-Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV): A randomized phase III trial.

Rudolph M. Navari

5 #9021-Phase III randomized double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting.

Steven M. Grunberg, MD

- Discussion

Michael Fisch, MD, MPH

7 #9023-A randomized crossover trial of venlafaxine (V) versus gabapentin (G) for hot flashes (HF) in breast cancer survivors.

Louise Bordeleau

8 #9024-A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: NCCTG study N04CA.

Charles L. Loprinzi, MD

9 #9025-Phase II study of gonadotropin-releasing hormone analogue for ovarian function preservation in hematopoietic stem cell transplantation patients.

Yee Chung Cheng

10 #9026-Value of early referral to improve fertility preservation outcomes in women with breast cancer.

Kutluk Oktay

11 #9027-Impact of 12 months of androgen-deprivation therapy (ADT) on cognitive function in men with nonmetastatic prostate cancer (PC): A matched cohort study.

Shabbir M.H. Alibhai, MD, MSc

12 #9028-The incidence of potential medication interactions including herbs and supplements among breast and prostate cancer patients during and after systemic anticancer therapy.

Nancy Kwon

- Discussion

Vered Stearns, MD

13 #9029-Pilot trial of a patient-specific cutaneous electrostimulation device (MC5-A Calmare) for chemotherapy-induced peripheral neuropathy.

Thomas J. Smith, MD

14 #9030-Signs and symptoms of peripheral neuropathy in adult survivors of childhood acute lymphoblastic leukemia (ALL): Associations with physical performance and chemotherapy doses.

Kirsten K. Ness

15 #9031-Comparison of in-dwelling catheters and talc pleurodesis in the management of malignant pleural effusions.

Todd L. Demmy, MD, FACS

16 #9032-Use of postoperative venous thromboembolism to predict disease-specific survival in cancer patients.

Rebecca Ann C Auer

17 #9033-Comparison of venous thromboemboli (VTE) incidence in cancer patients who are on statin therapy versus those not on statin therapy.

Thomas A Giever, DO, MBA

18 #9034-Screening for cardiac dysfunction and cardiovascular risk factors in childhood cancer survivors using the Children's Oncology Group (COG) long-term follow-up (LTFU) guidelines.

Saro Armenian

- Discussion

Charles L. Loprinzi, MD

19 #9035-Quality of life and symptoms in long-term survivors (LTS) of colorectal cancer (CRC): Results from NSABP protocol LTS-01.

Hiroko Kunitake

20 #9036-Quality-of-life results of an EORTC phase III randomized trial of adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases of solid tumors.

Riccardo Soffiatti

21 #9037-Cancer outcomes at end of life in Michigan.

May Darwish-Yassine

22 #9038-Predictors of patient misunderstanding of the goals of care at initiation of chemotherapy.

Inga Tolin Lennes

23 #9039-Hope, optimism, and survival in a randomized trial of first-line chemotherapy for patients with metastatic colorectal cancer.

Penelope Schofield

24 #9040-Patient-reported outcomes for determining prognostic groups in veterans with advanced cancer.

Victor Tsu-Shih Chang

25 #9041-Symptom burden in cancer survivors one year after diagnosis: A report from the American Cancer Society's studies of cancer survivors.

Qiuling Shi

- Discussion

Frederick J. Meyers, MD

Session Title: #332: Advancing Pain and Palliative Care Globally for Patients with Cancer

Session Type: Special Session

Date: Tuesday, June 8

Location: S504

Time: 9:00 AM - 12:00 PM

- Advancing Pain and Palliative Care Globally for Patients with Cancer

Jamie H. Von Roenn, MD

- Global Access to Cancer Pain Initiative

David Hill, PhD

- International Activities in Cancer and Palliative Care

Joe B. Harford, PhD

- International Drug Policy and Cancer Pain Control

James F. Cleary, MD

- International Education Activities in Palliative Care

- Panel: Palliative Care and Cancer in the Future

Kathleen M. Foley, MD

- Panel: Palliative Care and Cancer in the Future

Aziza T. Shad, MD

- Panel: Palliative Care and Cancer in the Future

Eduardo Bruera, MD

Session Title: #25: Closing the Loop: Evidence, Guidelines, Reporting, and Quality

Session Type: Education Session

Date: Tuesday, June 8

Location: S100a

Time: 9:30 AM - 10:45 AM

- Quality reporting, measurement and feedback

Craig Earle, MD

- Barriers to quality improvement initiatives

Sandra L. Wong, MD, MS

- Distilling research and evidence into opportunities for quality improvement

Gary H. Lyman, MD, MPH

Session Title: #95: Supportive Care for Patients with Non-small Cell Lung Cancer

Session Type: Education Session

Date: Tuesday, June 8

Location: E353

Time: 9:30 AM - 10:45 AM

- Management of dyspnea and pleural effusion in patients with lung cancer

David Feller-Kopman, MD

- Ancillary therapy for bone mets in the age of bisphosphonates

Vera Hirsh, MD

- Management of brain metastases in lung cancer patients.

Minesh P. Mehta, MD

Session Title: #45: Even Patients with Liver Dysfunction Can Get Chemotherapy!

Session Type: Education Session

Date: Tuesday, June 8

Location: E354b

Time: 9:45 AM - 11:00 AM

- Understanding assessment of liver function and viral hepatitis for the medical oncologist.

Lewis R. Roberts, PhD, MBChB

- Understanding the importance of hepatic function and dysfunction in metabolism of anticancer agents Delivering chemotherapy to the patient with liver dysfunction.

Timothy W. Synold, PharmD

- Management of dosing and side effects of specific chemotherapeutic agents.

Melanie B. Thomas, MD

Session Title: #138: The Best Treatment for Hepatic Metastases: What Is the Evidence?

Session Type: Clinical Problems in Oncology Session

Date: Tuesday, June 8

Location: E451a

Time: 9:45 AM - 11:00 AM

- Review the data supporting chemotherapy and molecular targeted therapy in management of hepatic metastases.

Heinz-Josef Lenz, MD

- Evidence for patient benefit using surgical and/or ablation for hepatic metastases.

Bryan M. Clary, MD

- The incorporation of conventional and stereotactic body radiation therapy into the treatment of hepatic metastases.

Christopher Willett, MD

Session Title: #256: Patient and Survivor Care

Session Type: Poster Discussion Session

Date: Tuesday, June 8

Location: E353

Time: 11:00 AM - 12:00 PM

- Patient and Survivor Care

Janet Lee Abrahm, MD

1 #9017-Evaluation of a urea/lactic acid-based topical keratolytic agent (ULABTKA) for prevention of capecitabine-induced hand and foot syndrome (HFS): NCCTG trial N05C5.

Sherry L Wolf

2 #9018-Using the Skindex-16 and CTCAE to assess rash symptoms: Results of a pooled-analysis (N0993).

Pamela J Atherton

3 #9019-CYTAR: A randomized clinical trial evaluating the preventive effect of doxycycline on erlotinib-induced folliculitis in non-small cell lung cancer patients.

Gael Deplanque

4 #9020-Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV): A randomized phase III trial.

Rudolph M. Navari

5 #9021-Phase III randomized double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting.

Steven M. Grunberg, MD

- Discussion

Michael Fisch, MD, MPH

7 #9023-A randomized crossover trial of venlafaxine (V) versus gabapentin (G) for hot flashes (HF) in breast cancer survivors.

Louise Bordeleau

8 #9024-A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: NCCTG study N04CA.

Charles L. Loprinzi, MD

9 #9025-Phase II study of gonadotropin-releasing hormone analogue for ovarian function preservation in hematopoietic stem cell transplantation patients.

Yee Chung Cheng

10 #9026-Value of early referral to improve fertility preservation outcomes in women with breast cancer.

Kutluk Oktay

11 #9027-Impact of 12 months of androgen-deprivation therapy (ADT) on cognitive function in men with nonmetastatic prostate cancer (PC): A matched cohort study.

Shabbir M.H. Alibhai, MD, MSc

12 #9028-The incidence of potential medication interactions including herbs and supplements among breast and prostate cancer patients during and after systemic anticancer therapy.

Nancy Kwon

- Discussion

Vered Stearns, MD

13 #9029-Pilot trial of a patient-specific cutaneous electrostimulation device (MC5-A Calmare) for chemotherapy-induced peripheral neuropathy.

Thomas J. Smith, MD

14 #9030-Signs and symptoms of peripheral neuropathy in adult survivors of childhood acute lymphoblastic leukemia (ALL): Associations with physical performance and chemotherapy doses.

Kirsten K. Ness

15 #9031-Comparison of in-dwelling catheters and talc pleurodesis in the management of malignant pleural effusions.

Todd L. Demmy, MD, FACS

16 #9032-Use of postoperative venous thromboembolism to predict disease-specific survival in cancer patients.

Rebecca Ann C Auer

17 #9033-Comparison of venous thromboemboli (VTE) incidence in cancer patients who are on statin therapy versus those not on statin therapy.

Thomas A Giever, DO, MBA

18 #9034-Screening for cardiac dysfunction and cardiovascular risk factors in childhood cancer survivors using the Children's Oncology Group (COG) long-term follow-up (LTFU) guidelines.

Saro Armenian

- Discussion

Charles L. Loprinzi, MD

19 #9035-Quality of life and symptoms in long-term survivors (LTS) of colorectal cancer (CRC): Results from NSABP protocol LTS-01.

Hiroko Kunitake

20 #9036-Quality-of-life results of an EORTC phase III randomized trial of adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases of solid tumors.

Riccardo Soffiatti

21 #9037-Cancer outcomes at end of life in Michigan.

May Darwish-Yassine

22 #9038-Predictors of patient misunderstanding of the goals of care at initiation of chemotherapy.

Inga Tolin Lennes

23 #9039-Hope, optimism, and survival in a randomized trial of first-line chemotherapy for patients with metastatic colorectal cancer.

Penelope Schofield

24 #9040-Patient-reported outcomes for determining prognostic groups in veterans with advanced cancer.

Victor Tsu-Shih Chang

25 #9041-Symptom burden in cancer survivors one year after diagnosis: A report from the American Cancer Society's studies of cancer survivors.

Qiuling Shi

- Discussion

Frederick J. Meyers, MD

Session Title: #69: Management of the Elderly Patient with Cancer

Session Type: Education Session

Date: Tuesday, June 8

Location: S100b

Time: 11:30 AM - 12:45 PM

- Under representation of the elderly in clinical trials and implications for comparative effectiveness research

Cary P. Gross, MD

- Assessing the elderly for therapy

Arti Hurria, MD

- Generalizability of clinical trials to the elderly

Elizabeth B. Lamont, MD, MS